ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Company profile
Ticker
NGM
Exchange
Website
CEO
David Woodhouse
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
NGM Biopharmaceuticals Australia Pty Ltd. ...
NGM stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
15 Apr 24
EFFECT
Notice of effectiveness
9 Apr 24
25-NSE
Exchange delisting
5 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Apr 24
POS AM
Prospectus update (post-effective amendment)
5 Apr 24
8-K
NGM Bio Announces Closing of Tender Offer
5 Apr 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 56.93 mm | 56.93 mm | 56.93 mm | 56.93 mm | 56.93 mm | 56.93 mm |
Cash burn (monthly) | 98.33 k | 4.04 mm | 10.34 mm | 13.34 mm | 9.05 mm | 11.64 mm |
Cash used (since last report) | 676.52 k | 27.79 mm | 71.16 mm | 91.79 mm | 62.29 mm | 80.06 mm |
Cash remaining | 56.25 mm | 29.14 mm | -14.23 mm | -34.86 mm | -5.36 mm | -23.13 mm |
Runway (months of cash) | 572.1 | 7.2 | -1.4 | -2.6 | -0.6 | -2.0 |
Institutional ownership, Q3 2023
73.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 96 |
Opened positions | 12 |
Closed positions | 24 |
Increased positions | 30 |
Reduced positions | 35 |
13F shares | Current |
---|---|
Total value | 49.20 bn |
Total shares | 61.65 mm |
Total puts | 300.00 |
Total calls | 400.00 |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Column | 18.14 mm | $19.41 bn |
Column Group L P | 11.20 mm | $146.09 mm |
EcoR1 Capital | 6.44 mm | $6.89 bn |
BLK Blackrock | 3.84 mm | $4.11 bn |
Topspin Fund | 3.32 mm | $77.67 mm |
Vanguard | 2.76 mm | $2.95 bn |
StepStone | 1.57 mm | $1.68 bn |
JPM JPMorgan Chase & Co. | 1.41 mm | $1.51 bn |
Acadian Asset Management | 1.19 mm | $1.28 mm |
Euclidean Capital | 992.17 k | $1.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Hsiao D Lieu | Common Stock | Dispose U | No | No | 0 | 19,349 | 0.00 | 0 | |
5 Apr 24 | Hsiao D Lieu | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.36 | 159,000 | 693.24 k | 0 |
5 Apr 24 | Hsiao D Lieu | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.84 | 150,000 | 126.00 k | 0 |
5 Apr 24 | Hsiao D Lieu | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.84 | 150,000 | 126.00 k | 0 |
5 Apr 24 | Hsiao D Lieu | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.84 | 100,000 | 84.00 k | 0 |
5 Apr 24 | Hsiao D Lieu | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.84 | 25,000 | 21.00 k | 0 |
5 Apr 24 | Hsiao D Lieu | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.84 | 190,000 | 159.60 k | 0 |
5 Apr 24 | Hsiao D Lieu | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 39,750 | 0.00 | 0 |
5 Apr 24 | Roger M Perlmutter | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17.24 | 46,238 | 797.14 k | 0 |
5 Apr 24 | Roger M Perlmutter | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.35 | 24,222 | 323.36 k | 0 |
News
Raymond James Downgrades NGM Biopharmaceuticals to Market Perform
12 Mar 24
NGM Biopharmaceuticals Q4 EPS $(0.33) Beats $(0.39) Estimate, Sales $165.00K Miss $560.00K Estimate
11 Mar 24
TD Cowen Downgrades NGM Biopharmaceuticals to Market Perform, Lowers Price Target to $1.55
28 Feb 24
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
26 Feb 24
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
26 Feb 24
Press releases
NGM Bio Announces Closing of Tender Offer
5 Apr 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI
22 Mar 24
Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm
22 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM
21 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTE
18 Mar 24